New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
07:01 EDTMYGNMyriad Genetics outlook still positive, says Cantor
After a judge denied Myriad's request for a preliminary injunction against a competitor and Myriad's stock decline more than 8% yesterday, Cantor says it expected the motion to be denied. The firm continues to believe that Myriad's position in the hereditary cancer testing market is strong, and it reiterates a $42 price target and Buy rating on the shares.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
07:11 EDTMYGNMyriad Genetics presented results from myPath Melanoma test clinical study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use